Abstract:Although many researchers of Parkinson's disease (PD) have shifted their focus from the central nervous system (CNS) to the peripheral blood, a significant knowledge gap remains between PD severity and the peripheral immune response. In the current study, we aimed to map the peripheral immunity atlas in peripheral blood mononuclear cells (PBMCs) from PD patients and healthy controls using single-cell RNA sequencing (scRNA-seq). Our study employed scRNA-seq analysis to map the peripheral immunity atlas in PD by profiling PBMCs from PD-Early, PD-Late patients and matched controls. By enlarging the blood sample size, we validated the roles of NK cells in numerous immune-related biological processes. We also detected the infiltration of NK cells into the cerebral motor cortex as the disease progressed, using human brain sections, and elucidated the communication between the periphery and CNS and its implications for PD. As a result, cell subpopulation atlases in PBMCs from PD patients and healthy controls along with differentially expressed genes in NK cells were identified by scRNA-seq analysis, representing 6 major immune cell subsets among which NK cells declined in the progression of PD. We further validated NK cell reduction in increasing samples and found that they participated in numerous immune-related biological processes and infiltration into the cerebral motor cortex as the disease proceeded, evidencingd the close communication between the peripheral immune response and CNS. Strikingly, XCL2 positively correlated with PD severity, with good predictive performance of PD and specific expression in subclusters C2 and C5 of NK cells. All these findings delineated the critical role of peripheral immune response mediated by NK cells in the pathogenesis of PD. NK cell-specific XCL2 could be used as a diagnostic marker for treating PD. The indispensable function of NK cells and NK cell-specific molecular biomarkers highlighted the implication of the peripheral immune response in PD progression. Trial registration: ChiCTR, ChiCTR1900023975. Registered 20 June 2019 - Retrospectively registered, https://www.chictr.org.cn/showproj.html?proj=31035 .

Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study

Association Between Peripheral Adaptive Immune Markers and Disease Progression in Parkinson's Disease.

Single-cell RNA sequencing reveals peripheral immunological features in Parkinson's Disease

Cytokine and Chemokine Map of Peripheral Specific Immune Cell Subsets in Parkinson's Disease

Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson's disease

Microglia and Astrocytes Dysfunction and Key Neuroinflammation-Based Biomarkers in Parkinson's Disease

Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson’s disease

Regulation of Mir-590-5p on Neurological Inflammation and Oxidative Stress and Its Biomarker Role in Parkinson’s Disease

Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice

Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease

Periphery and brain, innate and adaptive immunity in Parkinson's disease

Parkinson's Disease Peripheral Immune Biomarker Profile: a Multicentre, Cross-Sectional and Longitudinal Study

Neuroinflammation in Parkinson's disease: focus on the relationship between miRNAs and microglia

Activated Microglia in the Early Stage of a Rat Model of Parkinson's Disease: Revealed by PET-MRI Imaging by [18F]DPA-714 Targeting TSPO

Microglia P2Y6 receptor is related to Parkinson’s disease through neuroinflammatory process

Regulation of miR-590-5p on Neurological Inflammation and Oxidative Stress and Its Biomarker Role in Parkinson's Disease

GSDMD in Peripheral Myeloid Cells Regulates Microglial Immune Training and Neuroinflammation in Parkinson's Disease

Evidence for Peripheral Immune Activation in Parkinson's Disease.

Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets

The immune system in Parkinson's disease: what we know so far

Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia